Pregnancy
| |
Relapse during pregnancy, no. (%)
|
13 (11.21%)
|
DMT use during pregnancya, no. (%)
| |
Intentionally
|
6 (5.17%)
|
Accidentally (at first trimester)
|
38 (32.76%)
|
DMT type used (Intentionally)
| |
Interferon-beta
|
5 (83.33%)
|
DMT type used (Accidentally)
| |
Interferon-beta
|
15 (39.47%)
|
Dimethyl fumarate
|
7 (18.42%)
|
Fingolimod
|
12 (31.58%)
|
Rituximab
|
3 (7.89%)
|
ocrelizumab
|
1 (2.63%)
|
Postpartum period
| |
No. of pregnancies with postpartum relapses, no. (%)
| |
0
|
85 (73.28%)
|
1
|
24 (20.69%)
|
2
|
5 (4.31%)
|
≥ 3
|
2 (1.72%)
|
Time to first postpartum relapseb, median (IQR), days
|
171 (78–232)
|
DMT use during postpartum year, no. (%)
| |
None
|
69 (59.48%)
|
Interferon-beta
|
22 (18.97%)
|
Dimethyl fumarate
|
7 (6.03%)
|
Natalizumab
|
3 (2.57%)
|
Rituximab
|
4 (3.45)
|
Fingolimod
|
8 (6.90%)
|
Ocrelizumab
|
3 (2.57%)
|
Time to restart DMT after deliveryc (median, IQR), d
|
86 (29–201)
|